Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term erbB-2 Receptor. Found 16 abstracts

Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vondeheide RH, Albelda SM, June CH, Zhang PJ. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat. 2012 Jun;133(2):799-804.
Loo L, Capobianco JA, Wu W, Gao X, Shih WY, Shih WH, Pourrezaei K, Robinson MK, Adams GP. Highly sensitive detection of HER2 extracellular domain in the serum of breast cancer patients by piezoelectric microcantilevers. Anal Chem. 2011 May;83(9):3392-7.   PMCID: PMC3084889
Arias-Romero LE, Villamar-Cruz O, Pacheco A, Kosoff R, Huang M, Muthuswamy SK, Chernoff J. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Oncogene. 2010 Oct 28;29(43):5839-49.   PMCID: PMC2965784
Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clinical Cancer Research. 2010 Mar 15;16(6):1904-14.   PMCID: NIHMS352308
Freedman GM, Anderson PR, Li T, Nicolaou N. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer. 2009 Mar;115(5):946-51.   PMCID: PMC2993502
Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008 Nov 04;99(9):1415-25.   PMCID: PMC2576487
Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008 Feb;14(3):875-82.   PMCID: PMC2643368
Wang Y, Ikeda DM, Narasimhan B, Longacre TA, Bleicher RJ, Pal S, Jackman RJ, Jeffrey SS. Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology. 2008 Feb;246(2):367-75.
Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Molecular cancer research : MCR. 2007 Jan;5(1):71-85.
Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10;24(26):4324-32.
Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.[see comment]. Cancer Research. 2004 Sep;64(17):6200-6.
Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec;8(12):3718-27.
Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001 Jun 15;61(12):4750-5.
Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol. 2001 Oct;31(10):3016-25.
McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol. 2001 May 15;166(10):6112-7.
Weiner LM, Alpaugh RK, von Mehren M. Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins. Cancer Immunol Immunother. 1997 Nov;45(3-4):190-2.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term erbB-2 Receptor

erbB-2 Receptor Female Breast Neoplasms metabolism immunology therapeutic use Mice pathology Human US Gov't Support-PHS Male genetics Estrogen Receptors Tumor Cell Line Tissue Distribution Aged Middle Aged Neoplasm Antigens SCID Mice Monoclonal Antibodies Adult Progesterone Receptors Cultured Tumor Cells physiology Xenograft Model Antitumor Assays Bispecific Antibodies drug therapy pharmacology Ovarian Neoplasms 80 and over Aged IgG Receptors therapy Non-US Gov't Support Biological Tumor Markers administration & dosage Proto-Oncogene Proteins c-akt Animal radiotherapy Immunoglobulin Variable Region Dimerization effects analysis Radioimmunotherapy Kinetics Neoplastic Gene Expression Regulation Interleukin-2 Neoplasms Antibody-Dependent Cell Cytotoxicity Nude Mice adverse methods drug effects Hormone-Dependent Neoplasms Inbred ICR Mice Treatment Outcome Epidermal Growth Factor Receptor adverse effects Drug Administration Schedule CD56 Antigens Natural Killer Cells Signal Transduction T-Lymphocytes pd [Pharmacology] Gel Electrophoresis-Two-Dimensional Electricity Antineoplastic Combined Chemotherapy Protocols 0 (Isothiocyanates) Mammography Immunoglobulin Fc Fragments Segmental Mastectomy Flow Cytometry Fluorescence In Situ Hybridization Rabbits diagnosis Antineoplastic Combined Chemotherapy Immunologic Adjuvants classification Cytokines Antibody Affinity pk [Pharmacokinetics] Intracellular Fluid Inbred Strains Mice 67-43-6 (Pentetic Acid) Genetic Transcription Nitriles Immunoenzyme Techniques im [Immunology] Immunotoxins Astatine erbB-2) EC 2-7-1-112 (Receptor Immunotherapy Western Blotting Reproducibility of Results Calcium Signaling Middle Age 0 (Immunoglobulin Variable Region) Electrophoretic Mobility Shift Assay blood surgery toxicity aa [Analogs & Derivatives] Postmenopause Isothiocyanates 0 (Yttrium Radioisotopes) Non-US Gov't Research Support Peptide Fragments Local Neoplasm Recurrence Blood Chemical Analysis chemistry Pentetic Acid Progesterone use Immunohistochemistry Antibody Binding Sites deficiency Yttrium Radioisotopes Immunoglobulin Fragments Protocols Antibody Specificity Enzyme-Linked Immunosorbent Assay Prospective Studies biosynthesis Presenilin-2 pharmacokinetics Disease-Free Survival Tissue Array Analysis Lymphatic Metastasis Mitogen-Activated Protein Kinase Kinases Neoplasm Staging Kidney Genetic Transduction Survival Rate Neoplastic Cell Transformation antagonists & inhibitors Tertiary Protein Structure Inbred BALB C Mice Epitopes Cell Proliferation 0 (Immunotoxins) Extracellular Space Enzyme Inhibitors Extracellular Signal-Regulated MAP Kinases bi [Biosynthesis] rt [Radiotherapy] Messenger RNA Fluorescent Antibody Technique Response Elements N' -N-N'-N''-N''-pentaacetic acid) Lymphocyte Activation erbB-2 Genes
Last updated on Tuesday, October 10, 2017